Cyclooxygenase-2 promotes prostate cancer progression

Prostate

Volumn 53, Issue 3, 2002, Pages 232-240

  Fujita, Hiroshi ^a   Koshida, Kiyoshi ^a   Keller, Evan T ^b   Takahashi, Yoshitake ^a   Yoshimito, Tanihiro ^a   Namiki, Mikio ^a   Mizokami, Atsushi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cyclooxygenase 2; Prostate cancer; VEGF

Indexed keywords

COMPLEMENTARY DNA; CYCLOOXYGENASE 2; MESSENGER RNA; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENICITY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; BLOTTING, WESTERN; CELL DIVISION; CYCLOOXYGENASE 2; ENDOTHELIAL GROWTH FACTORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOENZYMES; LYMPHOKINES; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; NEOVASCULARIZATION, PATHOLOGIC; NITROBENZENES; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; TRANSFECTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036842180     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10152     Document Type: Article

References (50)

1. Landis SH, Murry T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J 1998;48:6-29.
2. Rose DP, Connolly JM. Dietary fat, fatty acids and prostate cancer. Lipid 1992;27:798-803.
3. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995;87:652-661.
4. Rose DP. Dietary fatty acids and prevention of hormone-responsive cancer. Proc Soc Exp Biol Med 1997;216:224-233.
5. Rose DP. Dietary fatty acids and cancer. Am J Clin Nutr 1997; 66:998S-1003S.
6. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA mRNA by prostaglandin E2, in human prostatic carcinoma cells. Br J Cancer 1997;75:1111-1118.
7. Hughes FM, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 2001;22:701-707.
8. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Prot Natl Acad Sci USA 1992;89:7384-7388.
9. Wiliams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100:1-5.
10. Morisset S, Patry C, Lora M, Brum-Fernandes AJ. Regulation cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin-1, tumor necrosis factor-alpha, glucocorticoids and 17beta-estradiol. J Rheumatol 1998;25:1146-1153.
11. Kujibu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991-7994.
12. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase2 gene expression in human colorectal adenomas adenocarcinomas. Gastroenterology 1994;107:1183-1188.
13. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T. Expression cyclooxygenase-1 and 2 in colorectal cancer. Cancer Res 1995;55:3785-3789.
14. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro SA. Hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-358.
15. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-3340.
16. Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T. Activation of matrix metalloprotease-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett 1999;460:145-148.
17. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxidase synthase-2. Cell 1995;83:493-501.
18. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulation angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
19. Gupta S, Strivastava M, Ahmad N, Bostwick DG, Mukhtar H. Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-78.
20. Yoshimura R, Sano H, Masuda C, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-596.
21. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GWH, Lalani EN. Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int 2000;86: 736-741.
22. Tanji N, Kikugawa T, Yokoyama M. Immunohistochemical study of cyclooxygenases in prostatic adenocarcinoma; relationship to apoptosis and bcl-2 protein expression. Anticancer Res 2000;20:2313-2320.
23. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001; 61:8617-8623.
24. Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA MRNA expression in prostate carcinoma. Neoplasia 2001;3:287-303.
25. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshomoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999;1438:120-130.
26. Chen C, Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987;7:2745-2752.
27. Wittwer CT, Ririe KM, Andrew DA, David RA, Gundry RA, Balis UJ. The LightCycler: A microvolume multisample flourimeter with rapid temperature control. Biotechniques 1997;22: 176-181.
28. Mizokami A, Saiga H, Matsui T, Mita T, Sugita A. Regulation of androgen receptor by androgen and epidermal growth factor in a human prostatic cancer cell line, LNCaP. Endocrinol Jpn 1992; 39:235-243.
29. Lowry OH, Rosenberg NJ, Farr AL, Randall AJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-275.
30. Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T. Tumor necrosis factor-α represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000;164:800-805.
31. Wang J, Sun L, Myeroff L, Wang X, Gentry E, Yang J, Liang J, Zborowska E, Markowitz S, Willson JK, Brattain MG. Demonstration that mutation of the type II transforming growth factor Β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995;270: 22044-22049.
32. Hsu AL, Ching TT, Wang DS, Song X, Rnagnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently bcl-2. J Biol Chem 2000;275:11397-11403.
33. Lim JTE, Piazza TA, Han EKH, Delohery TM, Li H, Finn TS, Buttyan R, Yamamoto H, Sperl GJ, Brendel K, Gross PH, Pamukcu R, Weinstein IB. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999;58:1097-1107.
34. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999;59:2223-2228.
35. Harada S, Keller ET, Fujimoto N, Koshida K, Namiki M, Matsumoto T, Mizokami A. Long-term exposure of necrosis factor α causes hypersensitivity to androgen and anti-androgen withdrawal phenomenon in LNCaP prostate cancer cells. Prostate 2001;46:319-326.
36. Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996;77:1862-1872.
37. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-686.
38. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274:27307-27314.
39. Soh JW, Mao Y, Kim MG, Pamukcu R, Li H, Piazza GA, Thompson WJ, Weinstein IB. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-jun NH2-terminal kinase 1. Clin Cancer Res 2000;6:4136-4141.
40. He TC, Chan TA, Vogelstein B, Kinzler KW. PPAR8 is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345.
41. Di Battista JA, Zhang M, Martel-Pelletier J, Fernandez J, Alaaeddine N, Pelletier JP. Enhancement of phosphorylation and transcriptional activity of the glucocorticoid receptor in human synovial fibroblasts by nimesulide, a preferential cyclooxygenase-2 inhibitor. Arthritis Rheum 1999;42:157-166.
42. DuBois RN, Shao J, Tujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxidase synthase-2. Cancer Res 1996;56:733-737.
43. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induced apoptosis and down-regulation bcl-2 expression in LNCaP cells. Cancer Res 1998;58: 4245-4249.
44. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-825.
45. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-4637.
46. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761-8766.
47. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 2000;60: 4959-4967.
48. Hahn D, Simak R, Steiner GE, Handisurya A, Susani M, Marberger M. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J Urol 2000;164: 506-510.
49. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;271:603-606.
50. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2, induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured Rat Muller cells. Invest Opthalmol Vis Sci 1998;39:581-591.